Department of Cardiovascular Medicine, Universitas Pelita Harapan, Tangerang, Banten, 15811, Indonesia.
Jakarta Varices Clinic, Jakarta, 12210, Indonesia.
Chin J Integr Med. 2024 Oct;30(10):927-937. doi: 10.1007/s11655-024-3665-0. Epub 2024 Jul 3.
Resveratrol is a non-flavonoid polyphenol that shows promise in reducing pro-inflammatory factors and maintaining endothelial function, which hints at its potential role in slowing atherosclerosis and preventing acute coronary events.
To study the cardioprotective effects of resveratrol on inflammatory mediators and endothelial function in patients with coronary artery disease (CAD).
A thorough search was conducted in databases (Cochrane Library, ProQuest, PubMed, LILACS, ScienceDirect, Springer, Taylor&Francis, CNKI, Wanfang, and Weipu) until September 24, 2023. The vasopro-inflammatory mediators, endothelial function and outcomes related to cardiovascular events were observed. Titles and abstracts were assessed, and bias was evaluated with Cochrane RoB 2.0. Heterogeneity of results was explored by meta-regression, certainty of evidence was assessed by the GRADE system, and conclusive evidence was enhanced by trial sequence analysis.
Ten randomized controlled trials and 3 animal studies investigated resveratrol's impact on inflammatory mediators and endothelial function. In primary prevention studies, meta-analysis showed a significant reduction (95% CI: -0.73 to -0.20; P=0.0005) in tumor necrosis factor-α (TNF-α) expression with resveratrol, demonstrating a dose-dependent relationship. No significant difference was observed in interleukin-6 (IL-6) expression with P=0.58 for primary prevention and P=0.57 for secondary prevention. Vascular endothelial nitric oxide synthase (eNOS) expression was significantly increased after resveratrol pre-treatment following CAD events. Secondary prevention studies yielded no significant results; however, meta-regression identified associations between age, hypertension, and lower doses with the extent of TNF-α alterations. High certainty of evidence supported TNF-α reduction, while evidence for IL-6 reduction and eNOS elevation was deemed low.
Resveratrol reduces TNF-α in individuals at risk for CAD, specifically 15 mg per day. However, its usefulness in patients with confirmed CAD is limited due to factors such as age, high blood pressure, and insufficient dosage. Due to the small sample size, the reduction of IL-6 is inconclusive. Animal studies suggest that resveratrol enhances endothelial function by increasing eNOS. (PROSPERO registration No. CRD42023465234).
白藜芦醇是一种非黄酮多酚，具有降低促炎因子和维持内皮功能的潜力，这表明它在减缓动脉粥样硬化和预防急性冠脉事件方面可能具有作用。
研究白藜芦醇对冠心病患者炎症介质和内皮功能的心脏保护作用。
我们对数据库（Cochrane 图书馆、ProQuest、PubMed、LILACS、ScienceDirect、Springer、Taylor&Francis、CNKI、万方和维普）进行了全面检索，检索截至 2023 年 9 月 24 日。观察血管炎症介质、内皮功能和心血管事件相关结局。评估标题和摘要，并使用 Cochrane RoB 2.0 评估偏倚。通过 meta 回归探索结果的异质性，使用 GRADE 系统评估证据的确定性，并通过试验序列分析增强结论性证据。
10 项随机对照试验和 3 项动物研究调查了白藜芦醇对炎症介质和内皮功能的影响。在一级预防研究中，meta 分析显示白藜芦醇治疗可显著降低肿瘤坏死因子-α（TNF-α）的表达（95%CI：-0.73 至-0.20；P=0.0005），且呈剂量依赖性关系。一级预防中，白细胞介素-6（IL-6）的表达无显著差异（P=0.58），二级预防中，IL-6 的表达也无显著差异（P=0.57）。在冠心病事件后，白藜芦醇预处理可显著增加血管内皮型一氧化氮合酶（eNOS）的表达。二级预防研究无显著结果，但 meta 回归确定了年龄、高血压和低剂量与 TNF-α改变程度之间的关联。高确定性证据支持 TNF-α的降低，而 IL-6 的降低和 eNOS 的升高证据质量较低。
白藜芦醇可降低有冠心病风险个体的 TNF-α，具体为每天 15mg。然而，由于年龄、高血压和剂量不足等因素，它在确诊冠心病患者中的应用效果有限。由于样本量较小，IL-6 降低的结论并不明确。动物研究表明，白藜芦醇通过增加 eNOS 来增强内皮功能。（PROSPERO 注册号：CRD42023465234）。
